<DOC>
	<DOCNO>NCT00623935</DOCNO>
	<brief_summary>The prognosis old individual acute myelogenous leukemia ( AML ) historically poor , 2 year disease-free survival rate &lt; 20 % report . Younger patient AML first complete remission routinely treat use full intensity ( myelo-ablative ) chemotherapy follow blood stem cell transplant . For old patient AML , full intensity therapy transplant greatly limit increased rate toxic effect relate type conditioning regimen . Reduced intensity ( non-myeloablative ) conditioning regimen use number clinical setting , include AML therapy , lessen regimen relate toxicity old patient . Recent data University Michigan Blood Marrow Transplant Program suggest improve survival individual &gt; 55 year age undergoing reduce intensity , transplant unrelated donor . This study investigate safety efficacy treatment option old patient AML , primary goal improve survival lifespan old patient AML .</brief_summary>
	<brief_title>Blood Stem Cell Transplantation Treatment Older Patients With Acute Myelogenous Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>For Study Registration : Age 55 70 year . Subjects diagnose AML ( &gt; 20 % myeloblast ) . For Proceeding Transplant : Subjects must either complete remission ( CR ) partial remission ( PR ) within 14 day prior admission . Subjects must &gt; 21 day since completion prior systemic chemotherapy radiation therapy ( include craniospinal XRT ) , prior admission . Organ function requirement reduce intensity ( FluBu2 ) regimen ( must meet within 21 day admission ) : Cardiac : LV Ejection Fraction &gt; 40 % MUGA Echocardiogram . Pulmonary : FEV1 FVC &gt; 40 % predict , DLCO &gt; 40 % predict . Renal : Serum creatinine &lt; 2.0 mg/dl . Not hemodialysis continuous venovenous filtration ( CVVH ) . Hepatic : serum total bilirubin &lt; 3.0 mg/dl AST / ALT &lt; 4x ULN Karnofsky &gt; 60 % . Organ function requirement full intensity ( FluBu4 ) regimen ( must meet within 21 day admission ) : Cardiac : LV Ejection Fraction &gt; 40 % MUGA Echocardiogram . Pulmonary : FEV1 FVC &gt; 50 % predict , DLCO ( correct hemoglobin ) &gt; 50 % predict . Renal : serum creatinine &lt; 2.0 mg/dl . Not hemodialysis continuous venovenous filtration ( CVVH ) Hepatic : serum total bilirubin &lt; 3.0 mg/dl AST / ALT &lt; 4x ULN . Karnofsky &gt; 60 % . For Study Registration : Subjects M3 AML ( FAB classification ) For Proceeding Transplant : Subjects exhibit sign progressive disease ( &gt; 20 % blast ) within 14 day prior admission transplant Patients uncontrolled viral fungal infection within prior 28 day . Patients HIV1 HIV2 positive . Uncontrollable medical psychiatric disorder</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>AML</keyword>
</DOC>